Premium
Growth Hormone Release in Hypertensive Adolescents Treated with Clonidine
Author(s) -
FALKNER BONITA,
ONESTI GADDO,
MOSHANG THOMAS,
LOWENTHAL DAVID T.
Publication year - 1981
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1981.tb01729.x
Subject(s) - clonidine , basal (medicine) , stimulation , medicine , endocrinology , hormone , growth hormone , adrenergic , receptor , insulin
The release of the growth hormone in the basal state and in response to strenuous exercise was studied in a group of 15 hypertensive adolescents receiving clonidine therapy and in a control group of 17 untreated adolescents of which ten were hypertensive volunteers and seven were healthy normotensive volunteers. Mean basal growth hormone in clonidine‐treated adolescents was 2.8 ± 0.50 S.E.M. ng/ml, compared to 2.7 ± 0.48 ng/ml in untreated adolescents. Following exercise stimulation, mean growth hormone was 14.8 ± 3.1 S.E.M. ng/ml in the treated group and 13.5 ± 2.8 ng/ml in the untreated group. Growth hormone release is regulated by α‐adrenergic receptor stimulation. Clonidine acts centrally by α‐adrenergic stimulation. However, this study demonstrates no effect of chronic clonidine therapy on growth hormone release.